ArticleNeuroImage. Clinical2026
Pediatric anti-NMDAR encephalitis: Neuroradiological presentation, cognitive outcome and volumetric MRI analysis.
Article in NeuroImage. Clinical, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is the most frequent autoimmune encephalitis in children and may cause long-term sequelae. Although MRI plays a key role in diagnosis and follow-up, its correlation with cognitive outcome remains unclear. We retrospectively reviewed pediatric cases of anti-NMDAR encephalitis diagnosed from 2007 to 2024, including only antibody-positive patients with at least one MRI. Clinical data encompassed presenting symptoms, EEG, therapies, relapses, and the latest neuropsychological assessment. MRI scans were evaluated by three neuroradiologists using a structured atrophy scale, and volumetric T1-weighted sequences, when available, were analyzed with Volbrain. Twenty-two patients (9 males, 13 females; median onset age 11.9 years) were included. The most frequent presenting symptoms were seizures (82%) and behavioral disturbances (59%), while EEG abnormalities were detected in 95%. At onset, 9 patients (41%) showed MRI abnormalities, most commonly fronto-parieto-occipital atrophy. Long-term cognitive follow-up (median 4.8 years), available for all patients, demonstrated that 80% of patients had normal or only mild deficits, but those with abnormal baseline MRI were more likely to develop long-term cognitive impairment, although the limited sample size precluded robust statistical analysis. Long-term MRI was available in 8 patients (median follow-up 10 years); volumetric analysis revealed parietal lobe volume loss in 6, including some with visually normal scans. Overall, baseline MRI alterations appeared associated with higher risk of subsequent cognitive deficits, while volumetric data highlighted subtle parietal atrophy even in patients with normal-appearing scans and, in some cases, without neuropsychological impairment. These findings support the complementary role of quantitative MRI and systematic neuropsychological monitoring in pediatric anti-NMDAR encephalitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.